Article
Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4.
Journal of infection in developing countries - 31 Jan 2020
Saafan Amal E, Abobaker Ashraf, Abbas Mohamed S, El-Gendy Ahmed
Abstract excerpt
INTRODUCTION: In Egypt, 15% of the populations are suffering from chronic hepatitis C especially genotype 4. Sofosbuvir was approved by FDA in December 2013 for treatment of HCV genotypes 2 and 3 in combination with Ribavirin, and for genotypes 1 and 4 in combination with Peg-IFN. Recently, polymorphism of different genes and plasma levels of IL-6 were utilized for better prediction of HCV clearance. This study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
